These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 15778976

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Is there a place for ribavirin in the treatment for renal transplant patients infected by hepatitis C virus?].
    Kamar N, Sandres-Saune K, Selves J, Durand D, Izopet J, Rostaing L.
    Nephrologie; 2003; 24(2):89-94. PubMed ID: 12723514
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Intrahepatic cytokine profile in renal-transplant patients infected by hepatitis C virus.
    Kamar N, Rostaing L, Sandres-Saune K, Selves J, Barthe C, Dubois M, Alric L, Durand D, Izopet J.
    J Med Virol; 2005 Aug; 76(4):482-8. PubMed ID: 15977245
    [Abstract] [Full Text] [Related]

  • 7. Relationship between serum ferritin, hepatic iron staining, diabetes mellitus and fibrosis progression in patients with chronic hepatitis C.
    D'Souza RF, Feakins R, Mears L, Sabin CA, Foster GR.
    Aliment Pharmacol Ther; 2005 Mar 01; 21(5):519-24. PubMed ID: 15740534
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The impact of nonalcoholic fatty liver disease and the metabolic syndrome on progression of fibrosis in patients with recurrent HCV after liver transplantation.
    Mindikoglu AL, Regev A, Casanova-Romero PY, Bejarano PA, Martinez EJ, Tzakis AG, Schiff ER.
    Transplant Proc; 2006 Jun 01; 38(5):1440-4. PubMed ID: 16797327
    [Abstract] [Full Text] [Related]

  • 11. Treatment of hepatitis C virus infection in thalassemia.
    Butensky E, Pakbaz Z, Foote D, Walters MC, Vichinsky EP, Harmatz P.
    Ann N Y Acad Sci; 2005 Jun 01; 1054():290-9. PubMed ID: 16339677
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Hepatic oxidative DNA damage correlates with iron overload in chronic hepatitis C patients.
    Fujita N, Horiike S, Sugimoto R, Tanaka H, Iwasa M, Kobayashi Y, Hasegawa K, Ma N, Kawanishi S, Adachi Y, Kaito M.
    Free Radic Biol Med; 2007 Feb 01; 42(3):353-62. PubMed ID: 17210448
    [Abstract] [Full Text] [Related]

  • 15. The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV-related chronic hepatitis.
    Loguercio C, Federico A, Masarone M, Torella R, Blanco Cdel V, Persico M.
    Am J Gastroenterol; 2008 Dec 01; 103(12):3159-66. PubMed ID: 18786125
    [Abstract] [Full Text] [Related]

  • 16. Liver fibrosis and hepatic stellate cells improvement of chronic hepatitis C patients by interferon-beta-1a with or without sustained viral response.
    Rao HY, Wei L, Li J, Zhang LF, Chen HY, Zhu LM, Liu F, Sun Y, Wang H.
    Hepatogastroenterology; 2009 Dec 01; 56(90):328-34. PubMed ID: 19579592
    [Abstract] [Full Text] [Related]

  • 17. Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis patients awaiting a kidney transplant.
    Kamar N, Ribes D, Izopet J, Rostaing L.
    Transplantation; 2006 Oct 15; 82(7):853-6. PubMed ID: 17038897
    [Abstract] [Full Text] [Related]

  • 18. [Serum levels of vascular endothelial growth factor in chronic hepatitis C patients treated with interferon alpha and ribavirin].
    Janczewska-Kazek E, Marek B, Pisula A, Kajdaniuk D, Witor A, Magiera M, Witor A.
    Wiad Lek; 2007 Oct 15; 60(3-4):120-3. PubMed ID: 17726862
    [Abstract] [Full Text] [Related]

  • 19. Marked iron overload related to ribavirin and iron sulfate treatment in a patient with active viral C cirrhosis.
    Jouannaud V, Cadranel JF, Dumouchel P, Cazier A, Capron D, Rochette J, Barbare JC.
    Eur J Gastroenterol Hepatol; 2009 Nov 15; 21(11):1310-3. PubMed ID: 19478679
    [Abstract] [Full Text] [Related]

  • 20. [Effect of pegylated interferon beta-1a therapy on the liver fibrosis in chronic hepatitis C: a semi-quantitative analysis].
    Rao HY, Li J, Zhang LF, Chen HY, Zhu LM, Wei L, Sun Y, Wang H.
    Zhonghua Yi Xue Za Zhi; 2008 Jan 08; 88(2):96-100. PubMed ID: 18353212
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.